Compare PESI & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PESI | LCTX |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.9M | 301.7M |
| IPO Year | 1996 | 1996 |
| Metric | PESI | LCTX |
|---|---|---|
| Price | $16.30 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 463.8K | ★ 906.7K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $642,000.00 | ★ $14,556,000.00 |
| Revenue This Year | $34.62 | $109.40 |
| Revenue Next Year | $77.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $8.14 | $1.00 |
| 52 Week High | $21.32 | $2.09 |
| Indicator | PESI | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 44.84 |
| Support Level | $14.18 | $1.00 |
| Resistance Level | $18.40 | $1.18 |
| Average True Range (ATR) | 1.25 | 0.05 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 7.09 | 32.14 |
Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.